Agentix Corp. (AGTX)
USD 0.16
(0.0%)
USD 0.16
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.37 Million USD | 0.0% |
| 2021 | -1.34 Million USD | 0.0% |
| 2019 | -121.17 Thousand USD | 9.64% |
| 2018 | -134.11 Thousand USD | 59.81% |
| 2017 | -333.72 Thousand USD | -14.3% |
| 2016 | -291.97 Thousand USD | -67.09% |
| 2015 | -174.73 Thousand USD | 16.17% |
| 2014 | -208.44 Thousand USD | -316.9% |
| 2013 | -50 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -401.13 Thousand USD | -13.43% |
| 2023 Q4 | -353.63 Thousand USD | 0.0% |
| 2023 Q3 | -353.63 Thousand USD | 16.66% |
| 2023 FY | - USD | 0.0% |
| 2023 Q1 | -164.65 Thousand USD | 91.84% |
| 2023 Q2 | -424.33 Thousand USD | -157.71% |
| 2022 Q3 | -186.97 Thousand USD | 23.19% |
| 2022 Q1 | -173.24 Thousand USD | 75.5% |
| 2022 Q2 | -243.42 Thousand USD | -40.51% |
| 2022 Q4 | -2.01 Million USD | -978.94% |
| 2021 Q4 | -706.96 Thousand USD | -226.21% |
| 2021 FY | - USD | 0.0% |
| 2021 Q1 | -1.28 Million USD | -10827.66% |
| 2021 Q3 | -216.71 Thousand USD | -31176.46% |
| 2021 Q2 | -692.91 USD | 99.95% |
| 2020 Q3 | -5032.00 USD | 58.19% |
| 2020 Q4 | -11.79 Thousand USD | -134.48% |
| 2020 Q1 | -30.43 Thousand USD | 14.92% |
| 2020 Q2 | -12.03 Thousand USD | 60.46% |
| 2019 Q1 | 42.59 Million USD | 104104.6% |
| 2019 FY | - USD | 9.64% |
| 2019 Q4 | -35.77 Thousand USD | 16.67% |
| 2019 Q3 | -42.93 Thousand USD | 99.9% |
| 2019 Q2 | -42.65 Million USD | -200.16% |
| 2018 Q3 | -25.61 Thousand USD | 49.31% |
| 2018 Q4 | -40.95 Thousand USD | -59.87% |
| 2018 Q1 | -64.47 Thousand USD | 49.23% |
| 2018 Q2 | -50.53 Thousand USD | 21.62% |
| 2018 FY | - USD | 59.81% |
| 2017 Q2 | -116.13 Thousand USD | 34.05% |
| 2017 Q1 | -176.09 Thousand USD | -37329.6% |
| 2017 Q3 | -53.25 Thousand USD | 54.15% |
| 2017 Q4 | -126.99 Thousand USD | -138.49% |
| 2017 FY | - USD | -14.3% |
| 2016 Q1 | -15.13 Thousand USD | 80.23% |
| 2016 FY | - USD | -67.09% |
| 2016 Q4 | 473.00 USD | 315.0% |
| 2016 Q2 | -25.05 Thousand USD | -65.57% |
| 2016 Q3 | -220.00 USD | 99.12% |
| 2015 Q1 | -69.24 Thousand USD | -157.58% |
| 2015 Q3 | -57.97 Thousand USD | 4.64% |
| 2015 FY | - USD | 16.17% |
| 2015 Q4 | -76.57 Thousand USD | -32.09% |
| 2015 Q2 | -60.79 Thousand USD | 12.21% |
| 2014 Q3 | -51.52 Thousand USD | 0.0% |
| 2014 FY | - USD | -316.9% |
| 2014 Q4 | -26.88 Thousand USD | 47.82% |
| 2013 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.069% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 76.863% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.861% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 92.103% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.459% |
| Mesoblast Limited | -62.38 Million USD | 97.801% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 10.696% |
| Genus plc | 73.7 Million USD | 101.861% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 79.252% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 61.326% |
| Marizyme, Inc. | -34.28 Million USD | 95.999% |
| ContraFect Corporation | -64.99 Million USD | 97.89% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 84.362% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 69.693% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 2.144% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 48.127% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 40.97% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -164.794% |
| Accustem Sciences Inc. | -3.74 Million USD | 63.385% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.156% |
| EV Biologics, Inc. | -1.26 Million USD | -8.257% |
| Q BioMed Inc. | -617.62 Thousand USD | -122.101% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 138.403% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -116.911% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 39.953% |
| Biomind Labs Inc. | -1.03 Million USD | -32.595% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 113.888% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 80.845% |
| Skye Bioscience, Inc. | -13.54 Million USD | 89.875% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 7.776% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -5387.024% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 64.685% |
| IMV Inc. | -35.52 Million USD | 96.138% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 91.356% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 45.173% |
| GB Sciences, Inc. | -1.41 Million USD | 3.39% |
| Alpha Cognition Inc. | -9.7 Million USD | 85.866% |
| HST Global, Inc. | -5303.00 USD | -25767.547% |
| CSL Limited | 4.78 Billion USD | 100.029% |
| Halberd Corporation | -74.27 Thousand USD | -1746.762% |
| Enzolytics Inc. | -2.12 Million USD | 35.356% |
| Resverlogix Corp. | -11.74 Million USD | 88.318% |
| Affymax, Inc. | -14.29 Million USD | 90.404% |
| SYBLEU INC | -141.57 Thousand USD | -868.953% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 55.216% |
| argenx SE | -216.02 Million USD | 99.365% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.521% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 212.716% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 8.483% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 462.09% |
| AVAX Technologies, Inc. | -6.11 Million USD | 77.559% |
| Zenith Capital Corp. | -8.6 Million USD | 84.06% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.448% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -7774.152% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 43.929% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -679.299% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.539% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 52.573% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -31.104% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 20500.892% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 21.614% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 28.588% |
| BioStem Technologies, Inc. | -7.55 Million USD | 81.84% |
| ONE Bio Corp. | 13.61 Million USD | 110.077% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -657.508% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 33.313% |
| LadRx Corporation | 412.28 Thousand USD | 432.722% |
| Cell Source, Inc. | -4.27 Million USD | 67.894% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -273.551% |
| Regen BioPharma, Inc. | 1.46 Million USD | 193.574% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -46.407% |
| NovAccess Global Inc. | -1.03 Million USD | -32.563% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 115.493% |
| Itoco Inc. | -1.86 Million USD | 26.605% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -261.35% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -22.917% |
| Kadimastem Ltd | -2.62 Million USD | 47.73% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -473.596% |
| CytoDyn Inc. | -18.02 Million USD | 92.391% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1635.763% |
| Mobile Lads Corp. | -2.24 Million USD | 38.793% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -11117.238% |
| Qrons Inc. | -40.08 Thousand USD | -3322.46% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -182.441% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 360.082% |
| Rebus Holdings, Inc. | -951 Thousand USD | -44.244% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -29.166% |
| International Stem Cell Corporation | 202 Thousand USD | 779.087% |
| Bioxytran, Inc. | -3.82 Million USD | 64.092% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2505.919% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 44.281% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 96.176% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -2948.347% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 49.899% |
| Neutra Corp. | -181.24 Thousand USD | -656.843% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 93.195% |
| PureTech Health plc | -11.62 Million USD | 88.202% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 93.195% |
| IXICO plc | -707 Thousand USD | -94.025% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 82.15% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.163% |
| CSL Limited | 4.73 Billion USD | 100.029% |
| Cellectis S.A. | -92.63 Million USD | 98.519% |